Innospera Pharma (Ingenew)

Ingenew develops anti-fibrotic drugs for high-value conditions with unmet medical needs and clear regulatory pathways. Innospera, a privately owned near-clinical-stage biotech company, develops small-molecule modulators of seven-transmembrane receptors involved in chronic and fibrotic diseases, including idiopathic pulmonary fibrosis and other conditions with urgent unmet needs.